Scientists are reporting results of the first frontline clinical trial to use targeted therapy to treat high-risk pediatric Hodgkin lymphoma. The study showed that the addition of brentuximab vedotin achieved excellent outcomes, reduced side effects, and allowed for reduced radiation…
Read More
EU Panel Endorses Duvelisib for CLL and Follicular Lymphoma
European Union approval has been recommended for duvelisib (Copiktra) for patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or refractory follicular lymphoma (FL) who have received at least two prior lines of therapy. The European Medicines Agency’s Committee for Medicinal Products…
Read More
Alecensa
NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. ALECENSA® ROCALECE10720 alectinib hydrochloride Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about Alecensa. It does not contain all the available…
Read More
Cholesterol starvation kills lymphoma cells
Scientists at Northwestern Medicine have developed a novel therapy to trick cancer cells into gobbling up what they think is their favorite food—cholesterol—which actually triggers their destruction. What appears to them as a cholesterol-loaded particle is actually a synthetic nanoparticle…
Read More
Potential treatment approach kills lymphoma while sparing healthy cells
Scientists at Scripps Research have demonstrated a promising new strategy for treating lymphomas, a group of cancers that begin in infection-fighting cells of the immune system called lymphocytes. The new approach uses natural cancer-targeting immune cells, known as natural killer…
Read More